| Literature DB >> 30979359 |
Holly Gagnon1,2, Molly Simmonite1, Kaitlin Cassady1, Jordan Chamberlain1,3, Erin Freiburger1, Poortata Lalwani1, Shannon Kelley1, Bradley Foerster4, Denise C Park5, Myria Petrou4, Rachael D Seidler6, Stephan F Taylor7,8, Daniel H Weissman1, Thad A Polk9.
Abstract
BACKGROUND: Aging is often associated with behavioral impairments, but some people age more gracefully than others. Why? One factor that may play a role is individual differences in the distinctiveness of neural representations. Previous research has found that neural activation patterns in visual cortex in response to different visual stimuli are often more similar (i.e., less distinctive) in older vs. young participants, a phenomenon referred to as age-related neural dedifferentiation. Furthermore, older people whose neural representations are less distinctive tend to perform worse on a wide range of behavioral tasks. The Michigan Neural Distinctiveness (MiND) project aims to investigate the scope of neural dedifferentiation (e.g., does it also occur in auditory, motor, and somatosensory cortex?), one potential cause (age-related reductions in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)), and the behavioral consequences of neural dedifferentiation. This protocol paper describes the study rationale and methods being used in complete detail, but not the results (data collection is currently underway).Entities:
Keywords: Aging; Cognition; Dedifferentiation; Functional MRI; GABA; Individual differences; Lorazepam; MR spectroscopy
Mesh:
Year: 2019 PMID: 30979359 PMCID: PMC6460537 DOI: 10.1186/s12883-019-1294-6
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Main study exclusion and inclusion criteria
| Exclusion Criteria | Inclusion Criteria |
|---|---|
| • Hearing problems or use of a hearing aid | • Age 18–29 years or 65 years and older |
Overview of experimental flow for the main study. Specific assessment titles are further outlined in Table 3
| Main Study | ||||
|---|---|---|---|---|
| Timepoint: | Enrolment | Session 1 | Session 2 | Session 3 |
| Enrolment: | ||||
| Eligibility screen | X | |||
| Informed consent | X | X | ||
| Condition Allocation | X | |||
| Assessments: | ||||
| Cognitive Impairment Screen | X | |||
| Fluid Intelligence Measures | X | X | ||
| Crystallized Intelligence Measures | X | |||
| Visual Function | X | X | ||
| Auditory Function | X | |||
| Tactile Function | X | |||
| Motor Function | X | X | ||
| MRI: | ||||
| fMRI Sensory Tasks | X | |||
| fMRI Resting State | X | |||
| DWI | X | |||
| MRS | X | |||
Main study behavioral tasks and fMRI session sequence
| Session | Measure | Domain | Approx. Time (min) |
|---|---|---|---|
| 1 – Behavior Only | MoCA | Cognitive Screening Tool | 10 |
| VPA_1 | Episodic Memory | 9 | |
| Faces in Noise | Visual | 2 | |
| Auditory Threshold | Auditory Screening Tool | 7 | |
| Sentences in Noise | Auditory | 7 | |
| Objects in Noise | Visual | 2 | |
| Symbol Search | Processing Speed | 4 | |
| VPA_2 | Episodic Memory | 3 | |
| Coding | Processing Speed | 3 | |
| Buildings in Noise | Visual | 2 | |
| Purdue Pegboard 1 | Motor | 5 | |
| Digits in Noise | Auditory | 4 | |
| Purdue Pegboard 2 | Motor | 3 | |
| Scenes in Noise | Visual | 2 | |
| Break | 5 | ||
| NIH Words-In-Noise Test | Auditory | 6 | |
| NIH Flanker Inhibitory Control and Attention Test | Executive Function | 3 | |
| NIH List Sorting Working Memory Test | Working Memory | 9 | |
| NIH Dimensional Change Card Sort Test | Executive Function | 5 | |
| NIH Pattern Comparison Processing Speed Test | Processing Speed | 3 | |
| NIH Picture Sequence Memory Test | Episodic Memory | 6 | |
| NIH Picture Vocabulary Test | Crystallized Intelligence | 3 | |
| NIH Oral Reading Recognition Test | Crystallized Intelligence | 3 | |
| NIH 9-Hole Pegboard Dexterity Test | Motor | 6 | |
| NIH Grip Strength Test | Motor | 3 | |
| 2 – Behavior + fMRI | RBMT Story 1 | Episodic Memory | 2 |
| Static Detection Threshold | Tactile | 3 | |
| Dynamic Threshold | Tactile | 3 | |
| Dynamic Threshold | Tactile | 5 | |
| Dynamic Threshold | Tactile | 5 | |
| NIH Visual Acuity Test | Visual | 2 | |
| RBMT Story 2 | Episodic Memory | 2 | |
| Functional Tactile Object Recognition | Tactile | 5 | |
| NIH 2-Minute Walk Endurance Test | Motor | 6 | |
| fMRI Task Preview | 10 | ||
| fMRI | 50 |
Drug study exclusion and inclusion criteria
| Exclusion Criteria | Inclusion Criteria |
|---|---|
| • Glaucoma | • Age 18–29 years or 65 years and older |
Overview of experimental flow for the drug study. Conditions and task orders are further outlined in Table 6
| Drug Study | |||
|---|---|---|---|
| Timepoint: | Enrolment | Session 1 | Session 2 |
| Enrolment: | |||
| Eligibility screen | X | ||
| Informed consent | X | X | |
| Condition Allocation | X | ||
| Intervention: | |||
| Groups 1A & 1B Placebo | X | ||
| Groups 1A & 1B Lorazepam | X | ||
| Groups 2A & 2B Placebo | X | ||
| Groups 2A & 2B Lorazepam | X | ||
| MRI: | |||
| Groups 1A & 2A fMRI Tasks (visual-motor) | X | ||
| Groups 1A & 2A fMRI Tasks (motor-visual) | X | ||
| Groups 1B & 2B fMRI Tasks (visual-motor) | X | ||
| Groups 1B & 2B fMRI Tasks (motor-visual) | X | ||
| All Groups fMRI Resting State | X | X | |
Drug pilot session orders
| Group | Session 1 | Session 2 |
|---|---|---|
| 1A | Placebo fMRI | Lorazepam fMRI |
| 1B | Placebo fMRI | Lorazepam fMRI |
| 2A | Lorazepam fMRI | Placebo fMRI |
| 2B | Lorazepam fMRI | Placebo fMRI |